Treatment withdrawal · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher treatment withdrawal compared with placebo (moderate certainty).
1 finding from 1 review
Frequency of adverse effects ‐ dizziness ( · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher adverse effects: dizziness compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effect: fatigue · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher adverse effects: fatigue compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: headache · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher adverse effects: headache compared with placebo (moderate certainty).
1 finding from 1 review
Somnolence · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher adverse effects: somnolence compared with placebo (moderate certainty).
1 finding from 1 review
Nausea · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher adverse effects: nausea compared with placebo (moderate certainty).
1 finding from 1 review
Vomiting · people with drug‐resistant focal epilepsy
Rufinamide may leads to higher adverse effects: vomiting compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Overall BPSD (multidomain) – not assessed · dementia
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Agitation · dementia
1 finding from 1 review
Intervention not reported
Depression – assessed in one study as "withdrawn behaviours" which included a lack of interest and sad mood · dementia
1 finding from 1 review
Intervention not reported
Anxiety ‐ not measured · dementia
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Quality of life ‐ not measured · dementia
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Dropouts ‐ not measured · dementia
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Final height and change in height · people with thalassaemia (any age)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse effects Oral glucose tolerance test (mg/dL) (at one year) · people with thalassaemia (any age)
1 finding from 1 review
Intervention not reported
Height SDS(at one year) · people with thalassaemia (any age)
1 finding from 1 review
Intervention not reported
Change in height SDS (difference between baseline and final visit at one year) · people with thalassaemia (any age)
1 finding from 1 review
Intervention not reported
Height velocity (cm/year) · people with thalassaemia (any age)
1 finding from 1 review
Intervention not reported
Height velocity SDS · people with thalassaemia (any age)
1 finding from 1 review
Intervention not reported
Change in height velocity SDS (difference between baseline and final visit at one year) · people with thalassaemia (any age)
1 finding from 1 review